Abstract
Purpose: Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab redu......
小提示:本篇文献需要登录阅读全文,点击跳转登录